Kardigan, Inc. (KARD)
$12.97-9.62%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.2B
- Beta
- 6.05
- P/E (TTM)
- -6.06
- Short % float
- 8.85%
- Days to cover
- 3.8
- SI change
- +73.0%
- 1W
- -3.85%
- 1M
- -31.92%
- vs SPY 1W
- -3.72%
- vs SPY 1M
- -34.42%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 20
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-65.7%
REV YoY-
ROE-109.4%
EPS YoY-
ROA-23.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-6.06
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.97
P/FCF-
EV/EBITDA-6.08
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.17
ALTMAN Z-
CURR RATIO8.72
ND/EBITDA-
BETA6.05
Company news
FAQ
- What is LOPJLB’s current signal on KARD?
- LOPJLB’s latest quantitative signal on Kardigan, Inc. (KARD) is SELL. Signals are updated daily.
- What market regime is KARD in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Kardigan, Inc. (KARD) do?
- Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its âCardiac Intelligenceâ platform to accelerate research and improve …